Disclosed herein is a therapeutic composition for prevention, elimination, treatment and management of neurodegenerative and neuro-muscular degenerative disorders and diseases in human and animal subjects, such as Amytrophic lateral sclerosis (ALS), Multiple sclerosis (MS), Alzheimer&rsquos disease (AD), Parkinson&rsquos disease (PD), and Muscular dystrophy (MD) and others, wherein the composition comprises a first component and a second component, said first component being mannitol in any of the forms thereof, or any of the mixtures of said forms, and said second component being ascorbic acid in any of the forms thereof such as the oxidised form, the reduced form, the mineral ascorbates, the fatty acid esters of ascorbic acid and others, or any of the mixtures of said forms. and further comprising zinc citrate, the composition being in any one of the following forms: (a) an intravenous(IV) fluid and the composition thereof is mannitol from about 1.8% w/v to about 25% w/v, zinc citrate from about 0.01% w/v to about 0.2% w/v and ascorbic acid from about 0.1% w/v to about 5% w/v, water qs, preservative qs, potassium phosphate buffer 7.4 pH, in about 100 ml of the said fluid and pro rata for other volumes (b) a syrup for oral administration, and comprising mannitol from about 5g to about 15g, ascorbic acid from about 5 g to about 12g and zinc citrate from about 120 mg to about 500 mg in about 30 ml of the said syrup and pro rata for other volumes, said composition further comprising BHT, ethyl alcohol, water, colouring agent, flavoring agent, pH adjusters, purified water as necessary (c) a solution suitable for intramuscular administration, said solution comprising mannitol from about 500 mg to about 1000 mg, ascorbic acid from about 250 mg to about 2000 mg, zinc citrate from about 10 mg to about 100 mg, water qs, benzyl alcohol preservative and sodium hydroxide and hydrochloric acid for pH adjustment in about 10 ml of the solution and pro rata for other volumes (d) a
